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Abstract
Background: Take-home naloxone (THN) programmes are an evidence-based opioid overdose prevention initiative.
Elevated opioid overdose risk following prison release means release from custody provides an ideal opportunity for
THN initiatives. However, whether Australian prisoners would utilise such programmes is unknown. We examined the
acceptability of THN in a cohort of male prisoners with histories of regular injecting drug use (IDU) in Victoria, Australia.
Methods: The sample comprised 380 men from the Prison and Transition Health (PATH) Cohort Study; all of
whom reported regular IDU in the 6 months prior to incarceration. We asked four questions regarding THN
during the pre-release baseline interview, including whether participants would be willing to participate in
prison-based THN. We describe responses to these questions along with relationships between before- and
during-incarceration factors and willingness to participate in THN training prior to release from prison.
Results: Most participants (81%) reported willingness to undertake THN training prior to release. Most were willing to
resuscitate a friend using THN if they were trained (94%) and to be revived by a trained peer (91%) using THN. More
than 10 years since first injection (adjusted odds ratio [AOR] 2.22, 95%CI 1.03–4.77), having witnessed an opioid
overdose in the last 5 years (AOR 2.53, 95%CI 1.32–4.82), having ever received alcohol or other drug treatment in
prison (AOR 2.41, 95%CI 1.14–5.07) and injecting drugs during the current prison sentence (AOR 4.45, 95%CI 1.73–
11.43) were significantly associated with increased odds of willingness to participate in a prison THN programme.
Not specifying whether they had injected during their prison sentence (AOR 0.37, 95%CI 0.18–0.77) was associated with
decreased odds of willingness to participate in a prison THN training.
Conclusion: Our findings suggest that male prisoners in Victoria with a history of regular IDU are overwhelmingly
willing to participate in THN training prior to release. Factors associated with willingness to participate in prison THN
programmes offer insights to help support the implementation and uptake of THN programmes to reduce opioid-
overdose deaths in the post-release period.
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Background
People who inject drugs (PWID), including opioids, are
disproportionately represented among the approximately
41,200 people incarcerated at any one time in Australian
prisons [1–3]. It is estimated that almost half of prison
entrants have ever injected drugs [4] and that approxi-
mately one quarter have injected in the month prior to
incarceration [5, 6]. People released from prison have
significantly higher rates of mortality than the general
population [7–10], with opioid overdose responsible for
a considerable proportion of excess risk, both in
Australia [11–16] and internationally [12, 13, 17–19]. Fatal
heroin overdoses (heroin only or poly-substance includ-
ing heroin) have increased every year since 2009 in
Victoria, Australia, with 220 overdose deaths involving
heroin occurring in 2017 [20]. Among prisoners and
people recently released from prison, witnessing and/or
experiencing opioid overdose is common [21, 22].
While strategies such as access to prison opioid
substitution therapy have demonstrated some efficacy
in reducing post-prison release opioid overdose risk
[10, 23], there is considerable evidence that naloxone,
an opioid antagonist, delivered via community-based or
prison-based take-home naloxone (THN) programmes
is effective in reducing the risk of opioid overdose.
THN programmes typically train participants in the
recognition and management of opioid overdoses and
equip participants with naloxone at completion of the
training. THN programmes have been found to in-
crease opioid overdose knowledge and reduce opioid-
related deaths among those trained and their broader
community [24–27]. People who have previously been
incarcerated and those involved with community-based
correction services report willingness to be trained in
how to use naloxone and to use it during opioid over-
doses [21, 28–30]. Despite this, published evaluations
of prison-based THN programmes and research into
the acceptability of THN programmes delivered to
people in prison are scarce [31].
Small-scale studies have evaluated the effectiveness of
prison-based THN programmes, demonstrating signifi-
cant improvements in participants’ overdose manage-
ment knowledge [32, 33], self-reported confidence to
manage an opioid overdose [22] and effective actions in
overdose simulations [34]. However, very few studies
have measured the impact of prison-based THN pro-
grammes. A THN programme implemented at the
Rikers Island gaol system in New York targeted training
and naloxone provision to visitors of inmates identified
as being at risk of overdose following release. Of the 283
participants, 40 participants responded to 70 overdose
incidents. Among those who witnessed an overdose event,
70% administered naloxone. The survival rate was 94% for
the 65 overdose events where data was available [35].
Evaluation of Scotland’s National Naloxone Program re-
ported 11,898 naloxone kits distributed between 2011
and 2013, of which 2273 were given to people leaving
prison. Subsequently, a 36% decrease in overdose-related
deaths among people released from prison in the previ-
ous 4 weeks was observed [36]. Prison-based THN pro-
grammes are being established in jurisdictions in the
USA [37–39] and Canada. None of these programmes
has yet been evaluated.
Very few prisoners have been trained in naloxone
provision in Australia. As a component of a broader
community-based THN programme, 18 prisoners were
trained in overdose prevention and naloxone provision at
the Alexander Maconochie Centre in the Australian
Capital Territory between 2011 and 2014, while Australia’s
first formal prison-based THN programme began at
Acacia Prison in Western Australia in 2016 [27, 40]. There
is no publicly available data pertaining to the numbers of
trainees from the Acacia Prison THN programme. Given
the small numbers of programme participants and lack of
programme evaluation at present, research is needed to
understand who would benefit from participating in a
prison-based THN programme, the possible impact of
prison-based THN programmes in Australia on post-
release opioid overdose, broader opioid overdose reduc-
tions among ex-prisoners’ family and social networks and
how best to support the implementation and scale-up of
prison-based THN. In this article, we examine the accept-
ability of prison-based THN among a cohort of men who
were regularly injecting drugs immediately prior to incar-
ceration and were about to be released from prison1 in
Victoria, Australia.
Methods
Study design
Our data are taken from baseline interviews with 400
participants of the Prison and Transition Health (PATH)
Cohort Study. PATH is a longitudinal cohort study of
400 men recruited in the weeks prior to release (baseline
interview) from one of the three prisons in Victoria,
Australia, who will be followed for 24 months after re-
lease. Operational limitations within Victoria’s female
prisons at the time of data collection prevented the re-
cruitment of women into PATH. Eligibility criteria in-
cluded reporting regular injecting drug use (IDU) in the
6 months prior to incarceration (defined as at least
monthly IDU), being aged over 18 years, providing in-
formed consent and expecting to be released within
12 weeks of the baseline interview. Participants were re-
cruited from one minimum (n = 108), medium (n = 111)
and maximum (n = 181) security facility. The maximum
security site was over-sampled to reflect its increased
prison population and annual discharges. Recruitment
methods included the use of posters, presentations at
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alcohol and other drug (AOD) group sessions and
‘town hall’ meetings, direct engagement with prisoners
during dosing clinics for opioid substitution therapy,
workplaces and on prison cell blocks. Prospective par-
ticipants completed an expression of interest form,
which was returned directly to researchers, to AOD
programme staff or in secure mail boxes around the
prisons. Upon receiving an expression of interest form,
researchers provided the prospective participant with
information about the study while screening for eligi-
bility. Baseline interviews were conducted between
September 2014 and May 2016. Participants com-
pleted a researcher-administered structured question-
naire that included socio-demographics, physical and
mental health, substance use, criminal activity and
pre-release support planning. The mean duration of
baseline interviews was 45 min (SD, 12 min; range,
26–73 min) and interviews were conducted a median
of 33 days (IQR, 13–62 days) prior to release. Ethics
approval for the PATH study was obtained from the
Alfred Hospital Human Research Ethics Committee
(79/12) and the Victorian Department of Justice
Human Research Ethics Committee (CF/14/10169).
Outcome measures
Participants’ beliefs and attitudes towards the accept-
ability of THN programmes were assessed through four
questions in the baseline questionnaire: (1)Would you
be willing to be trained on how to use naloxone in
prison and receive some to take with you when you are
released from prison?’; (2) ‘Would you be willing to be
trained on how to use naloxone soon after you are re-
leased from prison and receive some to take with you?’;
(3)‘If a friend had naloxone and was trained to use it,
and you overdosed on heroin, would you want them to
use it on you?’; and (4) ‘If you had naloxone and were
trained to use it and a friend overdosed on heroin,
would you use it on them?’. If a participant did not
know what naloxone (or ‘Narcan’, as it was known to
many prisoners) was, researchers provided a short de-
scription of it and its use. All THN measures had yes/
no responses.
Potential correlates
Potential correlates of willingness to engage in prison-based
THN training were selected from a review of literature or
were considered factors that could be used to inform a
prison-based THN trial. Examined variables included age
(< 35 years/35+ years), education (did not complete high
school/completed high school or alternative qualifications
such as a trade certificate), identifying as being Aboriginal
and/or Torres Strait Islander2 (yes/no), residential location
before prison (metropolitan/regional/other3), years since
first injected (< 10 years/10+ years), ever overdosed on
opioids (yes/no), witnessed an opioid overdose in the past
5 years (yes/no), heroin use in the month prior to incarcer-
ation (yes/no), illicit benzodiazepine use in the month be-
fore prison (yes/no), daily alcohol use in the month before
prison (yes/no), length of sentence (< 204 days/204+ days),
number of previous incarcerations (< 5 incarcerations/5+
incarcerations), having ever completed AOD treatment in
the community (yes/no), having ever completed AOD
treatment in prison (yes/no), having completed AOD treat-
ment in prison during that sentence (yes/no), self-reporting
being worried about substance use upon release (not wor-
ried/a little worried/very worried) and having injected any
drug during the current prison sentence (yes/no/declined
to answer).
Statistical analysis
Frequencies of responses to all questions about accept-
ability of prison-based THN programmes among PATH
participants were generated. Potential correlates were
described according to whether a participant reported
they would engage in prison-based THN training, and
we used bivariate logistic regression to examine associa-
tions between correlates and THN response to question
1, ‘Would you be willing to be trained on how to use na-
loxone in prison and receive some to take with you
when you are released from prison?’ A multivariable
model was constructed using all variables statistically
significant in bivariate analysis. Given the exploratory
nature of the research and the number of potential
correlates included, a stringent approach for construct-
ing a multivariable model was utilised to minimise over-
fitting. Only variables which were statistically significant
at p < 0.05 in bivariate analysis were included for multi-
variable analysis. A complete case approach was used,
resulting in the exclusion of 23 participants from ana-
lysis. All analyses were conducted using Stata 14 for
Windows [41].
Results
The median age of participants was 35 years (IQR 30–
42 years). Most participants (89%) were born in
Australia and 97% reported English as their primary
language. Among those born overseas, the median
number of years living in Australia was 28 (range 2–
51 years). Seventeen per cent identified as Aboriginal
and/or Torres Strait Islander. Most (82%) participants
did not complete high school or a high school equiva-
lent such as a trade certificate. Half (50%) reported re-
ceiving a Centrelink benefit (unemployment/study
allowance or a pension) as their primary source of in-
come and approximately one quarter (28%) reported
that their accommodation was unstable in the month
prior to incarceration. Participants had served a
median of five adult custodial sentences (IQR 3–9
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sentences) prior to their recruitment sentence. Most
(89%) had used heroin at some point in their lifetime.
The most commonly reported substances used in the
month before incarceration were crystal metham-
phetamine (84%), heroin (56%) and illicit benzodiaze-
pines (31%). Diverted opioid substitution medications
(methadone, buprenorphine or buprenorphine with
naloxone) (16%), oxycodone (15%) and morphine
(10%) were the most commonly used illicit pharma-
ceutical opioids in the month before incarceration. Al-
most half (42%) reported using both heroin and crystal
methamphetamine in the month prior to incarcer-
ation. Among the 220 participants who had suffered a
drug overdose (58%), the median number of overdoses
was 3 (IQR 2–5). More than half (62%) reported they
had witnessed a drug overdose.
Participants’ responses to THN acceptability questions
are shown in Table 1. The majority of participants (81%)
reported they would participate in THN training if of-
fered during their sentence, would participate in THN
training if offered after release from prison (79%), were
willing to use naloxone to revive a friend in the event of
an overdose (94%) and were willing to have a friend re-
vive them in the event of an overdose (91%).
Associations between potential correlates and THN
question 1 ‘Would you be willing to be trained on how
to use naloxone in prison and receive some to take with
you when you are released from prison?’ are described in
Table 2. Multivariable analysis showed reporting 10 years
or more since first injecting drugs (adjusted odds ratio
[AOR] 2.22, 95%CI 1.03–4.77), having witnessed an opi-
oid overdose in the past 5 years (AOR 2.53, 95%CI 1.32–
4.82), having ever completed AOD treatment in prison
(AOR 2.41, 95%CI 1.14–5.07) and having injected a sub-
stance during their current sentence (AOR 4.45, 95%CI
1.73–11.43) were associated with willingness to partici-
pate in prison-based THN. Declining to answer whether
they had injected a substance during their current period
of incarceration (AOR 0.37, 95%CI 0.18–0.77) was asso-
ciated with being less willing to participate in prison-
based THN.
Discussion
Prison and community-based THN training was en-
dorsed by the large majority of our sample of incarcer-
ated men with recent pre-incarceration histories of
regular IDU. Willingness to use naloxone on a friend
and willingness to be revived by a friend using nalox-
one were also extremely high. Our findings provide
strong evidence that most Victorian prisoners with
histories of IDU will accept THN training and
provision of naloxone upon release. In addition, our
identification of correlates of willingness to participate
in training, such as longer histories of IDU and expos-
ure to AOD treatment in prison, provide useful infor-
mation for targeting the promotion and delivery of
prison-based THN programmes. The reported propor-
tion of people with criminal justice system involve-
ment who report willingness to engage in naloxone
training has varied, with between 72% and 90% of
study participants reporting willingness to be trained
in naloxone administration [21, 29, 42], similar to our
findings. However, a study of individuals under com-
munity corrections orders in the USA reported varia-
tions in the proportion willing to receive opioid
overdose training (including naloxone) according to
individuals that reported never using opioids (32%)
relative to those that reported lifetime use of opioids
and had experienced an overdose (72%) and those who
had used opioids but never overdosed (59%) [30].
While our unadjusted analysis also found that those
who used heroin in the month prior to incarceration
and those who had experienced an opioid overdose
were more willing to participate in prison-based THN
training, neither of these factors remained significant
in the multivariable analysis. The higher THN accept-
ability in our study is likely attributable to partici-
pants’ patterns of substance use and exposure to
opioid overdoses. As noted, PATH participants re-
ported substantial poly-substance use at baseline
interview with most (90%) having ever used heroin,
more than half (58%) having experienced an opioid
overdose and many (62%) witnessing an opioid over-
dose in the preceding 5 years. This contrasts with
Cropsey et al.’s sample, where half (54%) reported
never having used an opioid and few (4%) reported
ever witnessing an opioid overdose.
Previous studies of prisoners and of people recently re-
leased from prison have found 88–90% of participants
reported being willing to administer naloxone to a peer/
friend in the event of an overdose [29, 32], consistent
Table 1 Acceptability of take-home naloxone among incarcerated
men who reported regular (at least monthly) injecting drug use
immediately prior to incarceration (n= 377)
Naloxone question No (%) Yes (%)
Would you be willing to be trained on
how to use naloxone in prison and receive
some to take with you when you are
released from prison?
73 (19) 304 (81)
Would you be willing to be trained on
how to use naloxone soon after you are
released from prison and receive some to
take with you?
81 (21) 296 (79)
If a friend had naloxone and was trained
to use it, and you overdosed on heroin,
would you want them to use it on you?
35 (9) 342 (91)
If you had naloxone and were trained to
use it and a friend overdosed on heroin,
would you use it on them?
23 (6) 354 (94)
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Table 2 Participant characteristics and modified logistic regression associations with willingness to engage in prison-based take-
home naloxone training among incarcerated men who reported regular injecting drug use immediately prior to incarceration
Variable No. (%) (n = 377) Yes to P-THN1 (%) p > |z| OR (95%CI) AOR (95%CI)*
Demographics
Age
< 35 years old 177 (47) 138 (78) 1 –
35+ years old 200 (53) 166 (83) 0.218 1.38 (0.83–2.30) –
Age of first IDU
< 18 years old 214 (57) 180 (84) 1 –
18+ years old 163 (43) 124 (76) 0.052 0.60 (0.36–1.00) –
Education
Did not complete high school 309 (82) 246 (80) 1 –
Completed high school2 68 (18) 58 (85) 0.285 1.49 (0.72–3.07) –
Aboriginal or Torres Strait Islander
No 314 (83) 251 (80) 1 –
Yes 63 (17) 53 (84) 0.444 1.33 (0.64–2.76) –
Accommodation before prison
Metropolitan 206 (55) 177 (86) 1 1
Regional 161 (43) 120 (75) 0.006 0.48 (0.28–0.81) 0.57 (0.30–1.08)
Other3 10 (3) 7 (70) 0.181 0.38 (0.09–1.56) 0.46 (0.09–2.25)
Drug and alcohol
Years since first injection
< 10 years 78 (21) 55 (71) 1 1
10+ years 299 (79) 249 (83) 0.012 2.08 (1.17–3.70) 2.22 (1.03–4.77)
Ever overdosed on opioids
No 157 (42) 114 (73) 1 1
Yes 220 (58) 190 (86) 0.001 2.39 (1.42–4.02) 1.35 (0.72–2.54)
Witnessed an opioid overdose in last 5 years
No 142 (38) 101 (71) 1 1
Yes 235 (62) 203 (86) 0 2.58 (1.53–4.33) 2.53 (1.32–4.82)
Used heroin in the month before prison (any route)
No 165 (44) 124 (75) 1 1
Yes 212 (56) 180 (85) 0.018 1.86 (1.11–3.12) 0.95 (0.49–1.83)
Used illicit benzodiazepines in the month before prison
No 262 (70) 206 (79) 1 –
Yes 115 (31) 98 (85) 0.138 1.57 (0.87–2.84) –
Daily alcohol use in the month before prison (28+ days)
No 300 (80) 237 (79) 1 –
Yes 77 (20) 67 (87) 0.116 1.78 (0.87–3.66) –
Prison
Length of sentence
< 204 days 186 (50) 137 (74) 1 1
204+ days 186 (50) 163 (88) 0.001 2.53 (1.47–4.37) 1.27 (0.65–2.48)
Number of previous incarcerations
< 5 incarcerations 164 (44) 118 (72) 1 1
5+ incarcerations 213 (56) 186 (87) 0 2.69 (1.58–4.55) 1.83 (0.96–3.46)
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with our findings. These high rates of willingness to ad-
minister naloxone to peers in the event of an opioid
overdose were demonstrated during the UK’s multicen-
tre prison-based naloxone on release pilot randomised
control trial (N-ALIVE). N-ALIVE sought to establish
the impact of prison-based THN programmes on opioid
overdoses among prisoners following release. However,
whilst the study was established with the intention of fa-
cilitating the use of THN by peers and family to reverse
prisoner overdose, two thirds of recorded naloxone ad-
ministrations from N-ALIVE kits were administered by
the prisoner to a peer [43]. We found no previous re-
search explicitly assessing factors influencing THN ac-
ceptability among people who were incarcerated at the
time of data collection, but the association between wit-
nessing an overdose and willingness to engage in THN
training is common among PWID who have been incar-
cerated [21, 29, 32]. We did not find that prison-based
THN acceptability was significantly affected by the types
of drugs used in the month prior to prison, in contrast
to Cropsey et al. [30], whose study of people on commu-
nity corrections orders reported significant differences
based on whether someone had used opioids. As noted
above, these differences may be due to differing patterns
of substance use and previous exposure to opioid over-
dose between samples.
The individual factors associated with high acceptabil-
ity of prison-based THN reported in our study provide
insights to support its implementation and uptake in
Victorian prisons and elsewhere.
Assessments of prisoner needs on reception at prison
or during sentences could be used to identify people
who may use opioids upon release and be at risk of opi-
oid overdose, those who have witnessed opioid over-
doses and those who had injected drugs over longer
periods for targeted promotion of prison-based THN
training. A systematic review of peer-based prison
intervention programmes found that peer-based pro-
grammes can be effective in improving blood-borne
virus (BBV) knowledge, reducing in-prison BBV trans-
mission risk behaviours and improving mental health
[44]. Individuals with lived experiences related to
long-term IDU and witnessing overdose (peers) could
also be used to increase uptake and coverage of prison
THN programmes or deliver THN training themselves.
Referrals to AOD treatment could also include an auto-
matic offer of prison-based THN training, or training
could be integrated into programmes that include AOD
treatment provision.
Our finding that heroin use in the month before incar-
ceration was not significantly associated with THN accept-
ability supports making prison-based THN programmes
Table 2 Participant characteristics and modified logistic regression associations with willingness to engage in prison-based take-
home naloxone training among incarcerated men who reported regular injecting drug use immediately prior to incarceration
(Continued)
Variable No. (%) (n = 377) Yes to P-THN1 (%) p > |z| OR (95%CI) AOR (95%CI)*
AOD treatment in the community—ever
No 118 (31) 90 (76) 1 –
Yes 259 (69) 214 (83) 0.149 1.48 (0.87–2.52) –
AOD Treatment in prison—ever
No 92 (24) 58 (63) 1 1
Yes 285 (76) 246 (86) 0 3.70 (2.15–6.36) 2.41 (1.14–5.07)
AOD treatment in prison—this sentence
No 197 (52) 150 (76) 1 1
Yes 180 (48) 154 (86) 0.022 1.86 (1.09–3.15) 1.15 (0.54–2.48)
Worried about substance use upon release from prison
Not worried 130 (34) 99 (76) 1 1
A little worried 150 (40) 120 (80) 0.437 1.25 (0.71–2.21) 0.76 (0.38–1.50)
Very worried 97 (26) 85 (88) 0.032 2.22 (1.07–4.59) 1.55 (0.66–3.67)
Injected drugs in prison during this sentence
No 191 (51) 147 (77) 1 1
Yes 126 (33) 119 (94) 0 5.09 (2.21–11.71) 4.45 (1.73–11.43)
Declined to answer 60 (16) 38 (63) 0.038 0.52 (0.28–0.96) 0.37 (0.18–0.77)
*Only variables which were significant at p < 0.05 during bivariate analysis were included in multivariable analysis
1P-THN refers to whether the participant reported willingness to participate in prison-based THN training as asked in Q1
2Includes high school completion equivalent (e.g. technical, further or industry-specific education courses)
3 Other denotes people who were itinerant in the month prior to incarceration and were unable to provide a postcode
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broadly accessible to all prisoners, rather than target-
ing THN programmes towards people based on types
of substance use pre-incarceration. While in the con-
text of community corrections others have found that
those with histories of opioid use were more likely to
report willingness to engage in THN training [30], the
outcomes reported from the Rikers Island THN
programme, in which almost half of the naloxone ad-
ministration events from participants occurred with
strangers [35], and the N-ALIVE trial, in which two
thirds of naloxone administration events were admin-
istered by the prisoner to another person [42, 43],
suggest a broad community-level overdose prevention
benefit from a prison THN programme. This would
require an approach that targets communities (e.g.
those impacted most by incarceration) as opposed to
individuals for THN programmes. Future research
should explore the potential impact of prison-based THN
programmes on not only the programme participants but
also on their broader networks and communities.
Because people who inject drugs whilst incarcerated
are more likely to return to IDU upon release [45], this
group should also be targeted for prison-based THN
programmes. The finding that people who declined to
answer whether they had injected drugs whilst incarcer-
ated were less likely to report willingness to engage in
prison-based THN programme highlights the sensitive
nature of a prisoner’s IDU status whilst incarcerated.
The potential perception among people in prison that
THN programme participation equates to an increased
risk of being identified as a drug user and being targeted
for drug interdiction activities needs to be considered in
implementing prison THN programmes.
Our study has several limitations. The accuracy of
self-report studies may be influenced by social desirabil-
ity and recall biases; however, numerous studies have
established that PWID can provide accurate recollection
of their AOD use histories [46–49]. While these findings
are taken from the baseline interviews of a longitudinal
study, they are in essence cross-sectional; as such, caus-
ation cannot be established. Prospective data collection
will allow for identification of individuals who overdose,
allowing for retrospective identification of pre-release
factors associated with increased overdose risk. This will
allow improved targeting of harm reduction interven-
tions, including prison-based THN programmes, to help
reduce post-release overdose risk. As PATH recruitment
criteria precluded women, youth and remanded pris-
oners, our findings may not be generalisable to these
groups. Our decision to only include potential corre-
lates in the multivariable model which were significant
at p < 0.05 in bivariate analyses may have resulted in
the omission of additional potential correlates. Differ-
ences between poly-drug types typically associated with
opioid overdose in Australia (typically benzodiazepines
and/or opioid pharmacotherapies, in combination with
heroin) [20] and other countries (e.g. overdoses driven
by synthetic opioids such as fentanyl in the USA or
Canada [50]) may limit the utility of our findings for
international prison-based THN programmes. Given
the overlap of non-injecting opioid use in prison with
IDU in prison categories, we were unable to assess the
independent relationship between willingness to par-
ticipate in a prison THN programme and non-injecting
opioid use. As we were unable to collect data from
people not participating in PATH, we are unable to
comment on the acceptability of prison-based THN
among non-participants. Finally, our findings do not
explore how the content, location, length or training
provider of a prison-based THN programme may influ-
ence willingness to engage training. Future explorations
of prison-based THN acceptability should broaden to
explore these factors.
Conclusion
People exiting prison face increased risk of opioid over-
dose in the months following release. With naloxone
available, opioid overdoses are rarely fatal. The over-
whelming level of interest among male prisoners with a
history of IDU in our study about participating in
prison-based THN programme training underscores the
crucial role of prison-based THN programmes in pre-
venting mortality among opioid users. This finding,
alongside the range of correlates of willingness to par-
ticipate in prison-based THN programme training, pro-
vides insights to help maximise prison-based THN
programme uptake and its impact on overdose mortality
prevention in Australia and elsewhere.
Endnotes
1Australian prisons are operated by state governments.
Victoria’s prison system consists of 15 facilities—13 for
men and 2 for women. Victorian facilities house mini-
mum, medium or maximum security prisoners exclu-
sively. There are no differences between a correctional
centre and prison, and prisoners frequently move
between facilities. Prisoners are assigned security ratings
based on factors including the nature of their offence,
length of sentence, previous offences and incidents
whilst incarcerated. Prisoners are detained at a facility in
accordance with their security rating. Security ratings
are adjusted based on prisoner behaviour.
2In Australia, Aboriginal and/or Torres Strait Islanders
are typically grouped in population research to encom-
pass all Indigenous Australians, whilst recognising the
distinct cultural heritage of each group. People identify-
ing as Aboriginal and/or Torres Strait Islanders are
over-represented among people in prison and people
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reporting IDU and are therefore routinely distinguished
in related research.
3‘Other’ includes people who were itinerant in the
month before incarceration and were unable to provide
a postcode of residence in the month before prison.
Metropolitan and regional residential locations also in-
clude people who were homeless but able to provide
residential postcodes.
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